David A Osborne
Nursing at Laporte Ave, Fort Collins, CO
License number
Colorado 710916
Issued Date
Jul 26, 2005
Renew Date
Feb 1, 2006
Expiration Date
Jan 31, 2008
Type
Certified Nurse Aide
Address
Address
915 La Porte Ave #2, Fort Collins, CO 80521
Professional information
Vice President, Product Development At Tolmar, Inc
Position:
Vice President, Product Development at TOLMAR, Inc
Location:
Fort Collins, Colorado Area
Industry:
Pharmaceuticals
Work:
TOLMAR, Inc
since Apr 2008
-
Vice President, Product Development
Dow Pharmaceutical Sciences Inc.
Sep 2003 - Mar 2008
-
VP, Product Development
Education:
University of Missouri-Rolla 1982 - 1985
PhD, Colloid Chemistry Missouri State University 1979 - 1982
B. Sci., Chemistry
PhD, Colloid Chemistry Missouri State University 1979 - 1982
B. Sci., Chemistry
Skills:
ANDA, Pharmaceutical Industry, Technology Transfer, Program Management, FDA, Product Development, Analytical Chemistry, Management, Drug Discovery, GMP, V&V, Clinical Development, Regulatory Affairs, R&D, Validation, HPLC, Quality Assurance, Biotechnology, Quality System, Drug Development, Team Building, GLP, Sop, Chromatography, Lifesciences
System For Percutaneous Delivery Of Opioid Analgesics
US Patent:
6355657, Mar 12, 2002
Filed:
Dec 30, 1999
Appl. No.:
09/475094
Inventors:
David W. Osborne - Fort Collins CO
Assignee:
Atrix Laboratories, Inc. - Fort Collins CO
International Classification:
A61K 3147
US Classification:
514327
Abstract:
Compositions and methods for the topical delivery of loperamide hydrochloride are disclosed. Novel solvent mixtures have been found to be beneficial in enhancing the penetration of loperamide hydrochloride through the skin.
Pharmaceutical Gel And Aerosol Formulations And Methods To Administer The Same To Skin And Mucosal Surfaces
US Patent:
6432415, Aug 13, 2002
Filed:
Dec 17, 1999
Appl. No.:
09/466380
Inventors:
David W. Osborne - Fort Collins CO
Russell J. Mumper - Lexington KY
Russell J. Mumper - Lexington KY
Assignee:
Axrix Laboratories, Inc. - Fort Collins CO
International Classification:
A61K 700
US Classification:
424400, 424401
Abstract:
Bioadhesive formulations to deliver, for both local and systemic effects, a wide variety of drugs of varying degrees of solubility are described. These formulations can be gels or aerosols and comprise a water-insoluble, pharmaceutically acceptable alkyl cellulose, a solvent system comprising a volatile solvent and water, a solubilizing agent or a dispersing agent, or a mixture thereof, and a pharmaceutical. These formulations can be made bioerodible and release the pharmaceutical in a controlled manner. Formulations further comprising a propellant such as 1,1-difluoroethane are also provided. The delivery can be made to a skin surface or to a mucosal surface. Methods for preparing and administering these formulations are also provided. Several specific examples using the anti-ulcer medication 2-amino-7-(1-methylethyl)-5-oxo-5H-[1]benzopyrano-[2,3-b]-pyridine-3-carboxylic acid are provided.
Analytical Methods For Measuring Synthetic Progesterone
US Patent:
2010030, Dec 2, 2010
Filed:
May 26, 2010
Appl. No.:
12/787495
Inventors:
David OSBORNE - Fort Collins CO, US
Paul WINKLER - Golden CO, US
Paul WINKLER - Golden CO, US
International Classification:
C12Q 1/02, G01N 33/48
US Classification:
435 29, 436 63
Abstract:
Embodiments relating to methods, processes and systems for measuring progesterone are provided. In particular, methods permit measurement and quantification of synthetic and/or endogenous progesterone from a progesterone-containing blood fluid sample by measuring a progesterone carbon isotope ratio by mass spectrometry and calculating the fraction of synthetic progesterone in the sample from the isotope ratio. Also provided are methods of evaluating bioequivalence of a synthetic progesterone composition using any of the methods provided herein. In an embodiment, methods of precise measurements of plasma levels are described for detection of progesterone analytes such as total progesterone, endogenous animal progesterone, and synthetic progesterone. Correcting for fluctuations in endogenous progesterone levels following application of synthetic progesterone allows a significant reduction in the number of test subjects required to evaluate bioequivalence of a synthetic progesterone composition.
Protectant For Uv-Induced Skin Damage
US Patent:
7399462, Jul 15, 2008
Filed:
Dec 14, 2004
Appl. No.:
11/011291
Inventors:
David W. Osborne - Fort Collins CO, US
Assignee:
QLT USA, Inc. - Fort Collins CO
International Classification:
A61Q 17/00, A61Q 17/04, A61Q 19/00
US Classification:
424 59, 424401, 424449
Abstract:
The present invention provides a method for protecting against UV radiation-induced skin damage. Specifically, compositions including dapsone are administered to provide UV protection. The dapsone compositions may be administered orally, or by other parenteral routes, such as topically, transdermally, by inhalation, and the like.
Topical Dapsone For The Treatment Of Acne
US Patent:
2007012, May 31, 2007
Filed:
Dec 12, 2006
Appl. No.:
11/637645
Inventors:
David Osborne - Fort Collins CO, US
International Classification:
A61K 31/135, A61K 8/40
US Classification:
424401000, 514646000
Abstract:
The present invention relates to a method of treating acne by topically applying a dermatological composition comprising dapsone. In addition to inflammatory lesions, the composition also treats non-inflammatory acne. The composition is formulated to include dapsone in a both a dissolved and microparticulate state.
Skin Penetration Enhancing Systems For Polar Drugs
US Patent:
2011019, Aug 11, 2011
Filed:
Feb 17, 2009
Appl. No.:
12/867875
Inventors:
David Osborne - Fort Collins CO, US
Pramod P. Sarpotdar - Rohnert Park CA, US
Arturo J. Angel - Santa Rosa CA, US
Inigo Saenz De Tejada - Madrid, ES
Maria Luisa Krauel - , US
Pramod P. Sarpotdar - Rohnert Park CA, US
Arturo J. Angel - Santa Rosa CA, US
Inigo Saenz De Tejada - Madrid, ES
Maria Luisa Krauel - , US
Assignee:
Action Medicines S.L. - Mardid
International Classification:
A61K 31/185, C07C 309/42, A61P 17/00
US Classification:
514576, 562 81
Abstract:
The invention relates to pharmaceutical compositions and related methods for the topical administration of polar drugs. In a particular embodiment, the invention relates to a pharmaceutical composition comprising an active pharmaceutical agent that is a polar drug, such as potassium 2,5-dihydroxybenzenesulfonate, at least one occlusive agent, and at least one stabilizer.
Topical Dapsone For The Treatment Of Acne
US Patent:
2003015, Aug 21, 2003
Filed:
Feb 20, 2002
Appl. No.:
10/081050
Inventors:
David Osborne - Fort Collins CO, US
International Classification:
A61L009/04, A61K007/42, A61K031/135
US Classification:
424/059000, 514/646000, 424/045000
Abstract:
The present invention relates to a method of treating acne by topically applying a dermatological composition comprising dapsone. In addition to inflammatory lesions, the composition also treats non-inflammatory acne. The composition is formulated to include dapsone in a both a dissolved and microparticulate state.
Imiquimod Formulation
US Patent:
2009018, Jul 16, 2009
Filed:
Jan 14, 2009
Appl. No.:
12/319978
Inventors:
Gareth Winckle - Petaluma CA, US
David W. Osborne - Fort Collins CO, US
David W. Osborne - Fort Collins CO, US
International Classification:
A61K 31/437
US Classification:
514293
Abstract:
Solutions of members of the imidazoquinoline family of drugs, such as imiquimod or an analog thereof, are made by combining the drug in a solvent system containing one or more non-aqueous solvents and a hydrogen bond forming compound, wherein the solvent system contains a low level of water.
Azithromycin For Treatment Of Skin Disorders
US Patent:
8143227, Mar 27, 2012
Filed:
Sep 4, 2008
Appl. No.:
12/231586
Inventors:
Gordon Jay Dow - Santa Rosa CA, US
Bhaskar Chaudhuri - San Jose CA, US
David Wade Osborne - Fort Collins CO, US
Barry Calvarese - Menlo Park CA, US
Bhaskar Chaudhuri - San Jose CA, US
David Wade Osborne - Fort Collins CO, US
Barry Calvarese - Menlo Park CA, US
Assignee:
Dow Pharmaceutical Sciences, Inc. - Petaluma CA
International Classification:
A61K 31/70
US Classification:
514 29, 536 74
Abstract:
Azithromycin has increased efficacy in treating acne and other skin conditions when administered systemically at low doses, below those previously known to produce a clinical antibiotic effect.